Keros Therapeutics Inc (KROS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $202.13M
Last updated: Nov 17, 2026 at 11:05 AM ET
Keros Therapeutics Inc (KROS) Earnings: Report Dates and Results
Keros Therapeutics (KROS) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Keros Therapeutics reported EPS of $0.70, above the -$0.96 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
KROS has an expected report date of Mar 2, 2027.
Earnings History
Of the 26 quarters below that had an estimate, KROS beat 12, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $40.01M, up 180.6% from $14.26M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.70 | -$0.96 | -$1.53 - -$0.56 | +172.92% | Beat | N/A | 4 | 3 up, 1 down | Nov 5, 2026 | $40.01M |
| Jun 30, 2026 | -$1.45 | -$1.25 | -$1.33 - -$1.20 | -16.00% | Miss | N/A | 5 | 0 up, 4 down | Aug 3, 2026 | N/A |
| Mar 31, 2026 | -$1.21 | -$0.73 | N/A | -66.23% | Miss | -133.4% | 5 | 1 up, 3 down | May 14, 2026 | $367000 |
| Dec 31, 2025 | -$0.86 | -$0.45 | -$0.65 - -$0.16 | -91.11% | Miss | N/A | 6 | 6 up, 0 down | Mar 4, 2026 | $385000 |
| Sep 30, 2025 | -$0.18 | -$1.11 | -$1.48 - -$0.26 | +83.78% | Beat | N/A | 8 | 0 up, 2 down | Nov 5, 2025 | $14.26M |
| Jun 30, 2025 | -$0.76 | -$1.13 | -$1.30 - -$0.88 | +32.74% | Beat | N/A | 6 | 1 up, 2 down | Aug 6, 2025 | $18.17M |
| Mar 31, 2025 | $3.62 | $0.01 | -$1.35 - $3.60 | N/A | N/A | N/A | 8 | 2 up, 0 down | May 6, 2025 | $211.25M |
| Dec 31, 2024 | -$1.14 | -$0.43 | -$1.63 - $3.49 | -166.98% | Miss | N/A | 10 | 0 up, 0 down | Feb 26, 2025 | $3.04M |
| Sep 30, 2024 | -$1.41 | -$1.28 | -$1.47 - -$1.11 | -10.16% | Miss | N/A | 15 | 0 up, 1 down | Nov 6, 2024 | $388000 |
| Jun 30, 2024 | -$1.25 | -$1.25 | -$1.43 - -$1.10 | 0.00% | In line | N/A | 10 | 0 up, 0 down | Aug 7, 2024 | $37000 |
| Mar 31, 2024 | -$1.21 | -$1.33 | -$1.62 - -$1.20 | +9.02% | Beat | N/A | 10 | 0 up, 0 down | May 8, 2024 | $83000 |
| Dec 31, 2023 | -$1.34 | -$1.37 | -$1.53 - -$1.22 | +2.19% | Beat | N/A | 11 | 0 up, 0 down | Feb 28, 2024 | $143000 |
| Sep 30, 2023 | -$1.33 | -$1.35 | -$1.46 - -$1.27 | +1.48% | Beat | N/A | 9 | 0 up, 0 down | Nov 6, 2023 | $8000 |
| Jun 30, 2023 | -$1.27 | -$1.35 | -$1.43 - -$1.22 | +5.93% | Beat | N/A | 9 | 0 up, 0 down | Aug 7, 2023 | N/A |
| Mar 31, 2023 | -$1.26 | -$1.14 | -$1.23 - -$1.05 | -10.53% | Miss | N/A | 7 | 0 up, 0 down | May 4, 2023 | N/A |
| Dec 31, 2022 | -$1.09 | -$1.10 | -$1.18 - -$0.99 | +0.91% | Beat | N/A | 7 | 0 up, 0 down | Mar 3, 2023 | N/A |
| Sep 30, 2022 | -$0.92 | -$1.26 | -$1.32 - -$1.09 | +26.98% | Beat | N/A | 6 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$1.13 | -$1.07 | -$1.13 - -$1.00 | -5.61% | Miss | N/A | 5 | 0 up, 0 down | Aug 4, 2022 | N/A |
| Mar 31, 2022 | -$1.01 | -$0.86 | -$1.08 - -$0.34 | -17.44% | Miss | N/A | 4 | 0 up, 0 down | May 5, 2022 | N/A |
| Dec 31, 2021 | -$0.30 | -$0.92 | -$1.01 - -$0.87 | +67.39% | Beat | N/A | 4 | 0 up, 0 down | Mar 9, 2022 | $20.00M |
| Sep 30, 2021 | -$0.87 | -$0.72 | -$0.81 - -$0.64 | -20.83% | Miss | N/A | 4 | 1 up, 0 down | Nov 4, 2021 | N/A |
| Jun 30, 2021 | -$0.67 | -$0.65 | -$0.76 - -$0.54 | -3.08% | Miss | N/A | 4 | N/A | Aug 5, 2021 | $100000 |
| Mar 31, 2021 | -$0.68 | -$0.58 | -$0.65 - -$0.51 | -17.24% | Miss | N/A | 4 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$0.49 | -$0.57 | -$0.62 - -$0.53 | +14.04% | Beat | N/A | 4 | N/A | Mar 25, 2021 | N/A |
| Sep 30, 2020 | -$0.60 | -$0.59 | -$0.68 - -$0.50 | -1.69% | Miss | N/A | 4 | N/A | Nov 10, 2020 | N/A |
| Jun 30, 2020 | -$0.62 | -$0.67 | -$1.18 - -$0.49 | +7.46% | Beat | N/A | 4 | N/A | Aug 13, 2020 | N/A |
| Mar 31, 2020 | -$5.11 | -$0.80 | N/A | -538.75% | Miss | N/A | N/A | N/A | Apr 8, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.82, a profit after a loss of $5.01 per share the year before. It was -$6.82 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.82 | N/A |
| Dec 31, 2024 | -$5.01 | N/A |
| Dec 31, 2023 | -$5.20 | N/A |
| Dec 31, 2022 | -$4.15 | N/A |
| Dec 31, 2021 | -$2.52 | N/A |
| Dec 31, 2020 | -$6.82 | N/A |
Frequently Asked Questions About KROS
When is Keros Therapeutics's next earnings date?
Keros Therapeutics's next earnings report is expected for Mar 2, 2027.
Did KROS beat earnings estimates last quarter?
Yes. Keros Therapeutics reported EPS of $0.70 for the quarter ended Sep 30, 2026, above the -$0.96 estimate, a 172.92% surprise.
What EPS do analysts expect from KROS next quarter?
The consensus EPS estimate for Keros Therapeutics for the quarter ending Dec 31, 2026 is -$1.69 from 9 analysts, with estimates from -$2.43 to -$1.46.
How often does KROS beat earnings estimates?
Keros Therapeutics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -7.63%.
KROS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors